The opposite prognostic significance of nuclear and cytoplasmic p21 expression in resectable gastric cancer patients

Journal of Gastroenterology

Volumn 49, Issue 11, 2014, Pages 1441-1452

  Huang, Yefei ^a   Wang, Weimin ^b   Chen, Yansu ^a   Huang, Yulin ^a   Zhang, Jianbing ^a,c   He, Song ^c   Tan, Yongfei ^b   Qiang, Fulin ^c   Li, Aiping ^a   Røe, Oluf Dimitri ^d,e   Wang, Shouyu ^a   Zhou, Yan ^b   Zhou, Jianwei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Yixing People's Hospital   (China)

^c Nantong Cancer Hospital   (China)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^e Levanger Hospital   (Norway)

Author keywords

Gastric cancer; Metastasis; p21; Prognostic biomarker; Tissue microarray

Indexed keywords

PROTEIN P21; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; TUMOR MARKER;

AGED; ARTICLE; CANCER PROGNOSIS; CELL MIGRATION; COHORT ANALYSIS; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; STOMACH CARCINOMA; TISSUE MICROARRAY; TRANSIENT TRANSFECTION; WILD TYPE; ADULT; CELL FRACTIONATION; CELL MOTION; CELL NUCLEUS; CYTOPLASM; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; STOMACH TUMOR; SURVIVAL; TUMOR CELL LINE; TUMOR INVASION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CELL MOVEMENT; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SUBCELLULAR FRACTIONS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84926614602     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0900-4     Document Type: Article

References (44)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127:679-95.
3. Zhao X, Dou W, He L, et al. MicroRNA-7 functions as an antimetastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. Oncogene. 2013;32:1363-72.
4. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275-92.
5. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7:415-28.
6. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003;3:453-8.
7. Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet. 2007;8:341-52.
8. Harper JW, Adami GR, Wei N, et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75:805-16.
9. Cmielova J, Rezacova M. p21Cip1/Waf1 protein and its function based on a subcellular localization (corrected). J Cell Biochem. 2011;112:3502-6.
10. Rodriguez R, Meuth M. Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress. Mol Biol Cell. 2006;17:402-12.
11. Komiya T, Hosono Y, Hirashima T, et al. p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin Cancer Res. 1997;3:1831-5.
12. Zirbes TK, Baldus SE, Moenig SP, et al. Prognostic impact of p21/waf1/cip1 in colorectal cancer. Int J Cancer. 2000;89:14-8.
13. Ferrandina G, Stoler A, Fagotti A, et al. p21WAF1/CIP1 protein expression in primary ovarian cancer. Int J Oncol. 2000;17: 1231-5.
14. Lu X, Toki T, Konishi I, et al. Expression of p21WAF1/CIP1 in adenocarcinoma of the uterine cervix: a possible immunohistochemical marker of a favorable prognosis. Cancer. 1998;82: 2409-17.
15. Kapranos N, Stathopoulos GP, Manolopoulos L, et al. p53, p21 and p27 protein expression in head and neck cancer and their prognostic value. Anticancer Res. 2001;21:521-8.
16. Ceccarelli C, Santini D, Chieco P, et al. Quantitative p21(waf-1)/ p53 immunohistochemical analysis defines groups of primary invasive breast carcinomas with different prognostic indicators. Int J Cancer. 2001;95:128-34.
17. Sarbia M, Gabbert HE. Modern pathology: prognostic parameters in squamous cell carcinoma of the esophagus. Recent Results Cancer Res. 2000;155:15-27.
18. Cheung TH, Lo KW, Yu MM, et al. Aberrant expression of p21(WAF1/CIP1) and p27(KIP1) in cervical carcinoma. Cancer Lett. 2001;172:93-8.
19. Besson A, Assoian RK, Roberts JM. Regulation of the cytoskeleton: an oncogenic function for CDK inhibitors? Nat Rev Cancer. 2004;4:948-55.
20. Kumar R, Hung MC. Signaling intricacies take center stage in cancer cells. Cancer Res. 2005;65:2511-5.
21. Al-Moundhri MS, Nirmala V, Al-Hadabi I, et al. The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients. J Surg Oncol. 2005;91:243-52.
22. Sohn D, Essmann F, Schulze-Osthoff K, et al. p21 blocks irradiation- induced apoptosis downstream of mitochondria by inhibition of cyclin-dependent kinase-mediated caspase-9 activation. Cancer Res. 2006;66:11254-62.
23. Xia W, Chen JS, Zhou X, et al. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res. 2004;10:3815-24.
24. Koster R, di Pietro A, Timmer-Bosscha H, et al. Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest. 2010;120:3594-605.
25. Xia X,MaQ, Li X, et al. Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer. BMC Cancer. 2011;11:399.
26. Gamboa-Dominguez A, Seidl S, Reyes-Gutierrez E, et al. Prognostic significance of p21WAF1/CIP1, p27Kip1, p53 and E-cadherin expression in gastric cancer. J Clin Pathol. 2007;60: 756-61.
27. Wang S, Wu X, Chen Y, et al. Prognostic and predictive role of JWA and XRCC1 expressions in gastric cancer. Clin Cancer Res. 2012;18:2987-96.
28. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965; 64:31-49.
29. Japanese Gastric Cancer A. Japanese classification of gastric carcinoma, 2nd English edition. Gastric Cancer. 1998;1:10-24.
30. Mackintosh KA, Fairclough SJ, Stratton G, et al. A calibration protocol for population-specific accelerometer cut-points in children. PLoS One. 2012;7:e36919.
31. Rodriguez-Vilarrupla A, Diaz C, Canela N, et al. Identification of the nuclear localization signal of p21(cip1) and consequences of its mutation on cell proliferation. FEBS Lett. 2002;531:319-23.
32. Wang S, Wu X, Zhang J, et al. CHIP functions as a novel suppressor of tumour angiogenesis with prognostic significance in human gastric cancer. Gut. 2013;62:496-508.
33. Shen L, Xu W, Li A, et al. JWA enhances As(2)O(3)-induced tubulin polymerization and apoptosis via p38 in HeLa and MCF-7 cells. Apoptosis. 2011;16:1177-93.
34. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56:337-44.
35. Cheng X, Xia W, Yang JY, et al. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochem Biophys Res Commun. 2010;403:103-7.
36. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-97.
37. Marrelli D, Roviello F, De Stefano A, et al. Risk factors for liver metastases after curative surgical procedures for gastric cancer: a prospective study of 208 patients treated with surgical resection. J Am Coll Surg. 2004;198:51-8.
38. Mattioli E, Vogiatzi P, Sun A, et al. Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer. J Cell Physiol. 2007;210:183-91.
39. Zhou BP, Liao Y, Xia W, et al. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neuoverexpressing cells. Nat Cell Biol. 2001;3:245-52.
40. Ma L, Young J, Prabhala H, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010;12:247-56.
41. Murata-Kamiya N, Kurashima Y, Teishikata Y, et al. Helicobacter pylori CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells. Oncogene. 2007;26:4617-26.
42. Lilien J, Balsamo J. The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/dephosphorylation of betacatenin. Curr Opin Cell Biol. 2005;17:459-65.
43. Jung IM, Chung JK, Kim YA, et al. Epstein-Barr virus, betacatenin, and E-cadherin in gastric carcinomas. J Korean Med Sci. 2007;22:855-61.
44. Zhang Y, Yan W, Jung YS, et al. PUMA cooperates with p21 to regulate mammary epithelial morphogenesis and epithelial-tomesenchymal transition. PLoS One. 2013;8:e66464.